Search the Newsreel

Revvity stock holds firm as diagnostics and life sciences revenue support valuation

Revvity Inc. (RVTY) stock is supported by its robust diagnostics and life sciences revenue streams, strong cash generation, and disciplined margin management. The company, formerly PerkinElmer, has strategically focused on higher-margin biomedical and analytics operations. Investors are evaluating Revvity's growth prospects within the broader …

Revvity Signals for Startups: Guide for Emerging Biotechs

Revvity has launched "Revvity Signals for Startups," a new program offering enterprise-grade informatics software with guided onboarding and pre-configured environments for early-stage biotechnology companies. This initiative aims to help emerging biotechs establish structured data capture and repeatable workflows from the outset, moving beyond basic …

Sei Investments Co. Boosts Stock Position in Revvity Inc. $RVTY

PKI5144058 Bond Risk Profile

This article provides a risk profile for the Revvity, Inc. 2.55% 15-MAR-2031 bond (PKI5144058). It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors make informed decisions. The platform also offers access to analyst ratings …

Revvity, Inc. (RVTY) stock price, news, quote and history

This page provides comprehensive financial information for Revvity, Inc. (RVTY), including its stock price, historical data, key statistics, company overview, and recent news. It details the company's solutions in health sciences, its market performance, analyst ratings, and financial highlights, positioning it within the Diagnostics …

Revvity, Inc. (RVTY) Q1 2024 Earnings Report - Results, Call & Slides

Revvity, Inc. (RVTY) released its Q1 2024 earnings report, surpassing analyst expectations with an actual EPS of $17.16 against a consensus of $16.51 and actual revenue of $11.38 billion, beating the expected $11.33 billion. Despite beating estimates, the company experienced a year-over-year revenue growth …

Revvity Inc. stock underperforms Friday when compared to competitors

Revvity Inc. (RVTY) stock fell 2.39% to $110.47 on Friday, underperforming the broader market. This drop occurred despite a favorable trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. The decline ended a three-day winning streak for Revvity …

Revvity Developing Automated Platform for Tuberculosis Testing

Revvity is developing the T-SPOT A201, an automated platform for high-volume latent tuberculosis testing, with a planned launch in the second half of 2027 pending regulatory approval. This system is designed for large clinical laboratories to manage high sample volumes efficiently, reducing hands-on time …

Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan

Revvity, Inc. Vice President and CAO, Anita Gonzales, sold 85 shares of common stock on July 20, 2026, for $109.48 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on November 7, 2025. Following the sale, Ms. Gonzales directly holds …

Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs

Revvity has announced the development of the T-SPOT A201, a new high-throughput automated platform for latent tuberculosis (TB) detection. This system is designed to provide high-volume clinical laboratories with an efficient and scalable solution, processing up to 384 samples in an 8-hour shift. The …

Revvity Number of Employees 2026 | Employee Count & Headcount Data

Revvity, Inc. (RVTY) has approximately 11,058 employees worldwide as of March 2026, a 3.3% decline from 2023 but a slight increase from its 2024 low. The company is actively hiring, with 1,000 active job postings in 2026, an 11.5% increase from 2025. Although overall …

How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning

Revvity recently launched its Signals for Startups program, providing biotech firms with enterprise-grade informatics tools, and released its 2026 Impact Report detailing initial Scope 3 emissions and a grant initiative. These actions demonstrate Revvity's strategy to combine product innovation in scientific software with a …

Revvity to Launch Signals for Startups for Emerging Biotech Companies

Revvity, Inc. is launching "Signals for Startups," a new program for early-stage biotechnology companies in late July 2026. This initiative aims to provide scalable digital informatics capabilities, enterprise-grade Signals software, and guided onboarding to accelerate scientific innovation and research productivity. The program is expected …

Revvity Inc. Stock Slides 3.4%, Underperforms Peers

Revvity Inc. stock experienced a 3.4% slide, causing it to underperform compared to its peers. The article, sourced from Dow Jones, notes this decline in Revvity's market performance. Further details on the reasons for the underperformance require logging in to the Webull platform.

Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later

Revvity's Signals Software business is launching "Signals for Startups," a new program designed to provide emerging biotech companies with scalable informatics capabilities. This program offers access to Signals software, guided onboarding, and best-practice configurations to help early-stage biotechs accelerate innovation and improve scientific productivity. …

Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation

Revvity Inc. (US76155R1086) stock remains stable, supported by its Q1 2026 performance, which showed low single-digit revenue growth and expanded adjusted operating margins. The company reiterated its full-year 2026 guidance, expecting continued growth and margin expansion through cost initiatives and a focus on higher-value …

Precision Trading with Revvity Inc. (RVTY) Risk Zones

This article details precision trading strategies for Revvity Inc. (RVTY), highlighting a weak near-term sentiment but an exceptional 38.7:1 risk-reward setup targeting an 11.3% gain against 0.3% risk. It provides specific entry, target, and stop-loss zones for Long, Breakout, and Short positions based on …

Revvity Inc. stock underperforms Monday when compared to competitors

Revvity Inc. (RVTY) shares dropped 3.37% on Monday, closing at $106.44. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also declining. This marks the second consecutive day of losses for Revvity stock.

Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One

Revvity Signals Software is launching "Signals for Startups," a new program designed to help emerging biotechnology companies establish scalable informatics capabilities early in their development. This program provides early-stage biotechs with access to enterprise-grade Signals software, guided onboarding, and tailored configurations to accelerate innovation …

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

Revvity, Inc. (NYSE: RVTY) has published its 2026 Impact Report, detailing its sustainability, social, and governance initiatives and performance. The report highlights the company's commitment to responsible business practices, including the disclosure of Scope 3 emissions for the first time and a reduction in …

RVTY (RVTY) investor files notice to sell 85 common shares

Anita Gonzales, an investor in RVTY (Revvity, Inc.), has filed a Form 144 notice indicating a proposed sale of 85 common shares. The shares, valued at $9,305.80, were acquired as compensation via restricted stock vesting in April 2022 and are scheduled to be sold …

Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing

Revvity, Inc. is delisting its 1.875% Notes due 2026 from the New York Stock Exchange LLC. The removal is being conducted under Section 12(b) of the Securities Exchange Act of 1934, with both the Exchange and the issuer affirming compliance with applicable regulatory requirements.

Revvity stock trades steadily as recent earnings highlight margin focus

Revvity Inc. (RVTY) is strategically shifting its business towards higher-margin diagnostics and life-science tools, as evidenced by its latest quarterly results. Despite a mid-single-digit revenue decline, the company reported improved adjusted profitability and cash generation, underscoring a focus on margin expansion and optimized product …

PKI5144059 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Revvity, Inc. 3.625% 15-MAR-2051 bond (PKI5144059 FINRA). It details the current coupon rate of 3.63% and highlights that the next interest payment is scheduled for September 15, 2026. The page offers an overview of the bond's …

XS1405780617 Bond Risk Profile

This page provides a risk profile for the Revvity, Inc. 1.875% bond, maturing on July 19, 2026, with the identifier XS1405780617, traded on the Stuttgart Stock Exchange. It offers an overview of the bond, including coupon and redemption details, and highlights key metrics for …

Revvity stock trades steady as genomics and diagnostics revenue underpins valuation

Revvity stock is underpinned by its growing focus on genomics, diagnostics, and life science tools, evidenced by mid-single-digit revenue growth and a shift towards higher-margin consumables and services. The company's strategy involves recurring revenue streams, strong operational performance, and strategic acquisitions in high-growth areas, …

Revvity, Inc. (PKN) Q1 2024 Earnings Report - Results, Call & Slides

This article details Revvity, Inc.'s (PKN) Q1 2024 earnings report, revealing the company beat both EPS and revenue expectations. Revvity reported an actual EPS of €0.86 against a consensus of €0.82 and actual revenue of €568.10M against an expected €565.76M. The report also includes …

PKI5255604 Bond Profile — Key Metrics

This article provides key metrics for the PKI5255604 bond issued by Revvity, Inc. It details the bond's coupon rate, maturity date, outstanding amount, and gives an overview of Revvity, Inc.'s business operations in life sciences and diagnostics. The bond has a 2.25% coupon rate …

Revvity stock trades steadily as recent earnings highlight growth and margin pressure

Revvity stock is reportedly trading steadily, reflecting a balance between growth in diagnostics and life sciences and ongoing margin pressures. The company reported approximately $2.8 billion in total revenue for fiscal 2023, emphasizing a strategic shift towards higher-growth areas like genomics and cell analysis. …

Revvity (RVTY) Q4 2025 earnings summary

Revvity (RVTY) reported strong Q4 2025 results with revenue of $772 million, up 6% year-over-year, and adjusted EPS of $1.70, a 20% increase. The company exceeded initial guidance, driven by robust performance in its Diagnostics and Reproductive Health segments, and completed over $800 million …

Revvity (RVTY) Investor Day 2024 Summary

Revvity's 2024 Investor Day highlighted its transformation into a focused life sciences and diagnostics company, marked by strategic divestitures and key acquisitions. The company has improved its operating margin and free cash flow conversion, with recurring revenue now making up 80% of its total …

Revvity (RVTY) Stock Still Looks Undervalued On Cash Flow But Overvalued On Earnings

Revvity (RVTY) stock presents a mixed valuation picture, appearing undervalued based on its Discounted Cash Flow (DCF) model, which points to a 22.7% upside, partly due to the integration of its AI software with Anthropic’s Claude. However, the stock looks overvalued on an earnings …

REVVITY INC : TD COWEN RAISES TARGET PRICE TO $130 FROM $120

TD Cowen has increased its target price for Revvity Inc. to $130, up from the previous $120. This adjustment by the investment bank reflects a more optimistic outlook on the company's financial performance or future prospects.

Revvity (RVTY) TD Cowen 46th Annual Health Care Conference Summary

Revvity (RVTY) presented at the TD Cowen 46th Annual Health Care Conference, highlighting strong Q4 performance across various segments and outlining an organic growth guidance of 2%-3% for 2026. The company anticipates significant margin expansion in late 2026 and early 2027 due to cost …

Revvity jumps 13% on 9.9M shares, but inactive Trend Signal tempers the range-top move

Revvity closed at $113.0 after a volume-backed weekly advance, leaving the diagnostics stock just 4.4% below its 52-week high while Sharemaestro’s broader signal read remains balanced.